We are live on ! Find out more
BHST icon

BioHarvest Sciences

1.30 USD
-0.02
1.52%
At close Updated Nov 20, 4:00 PM EST
1 day
-1.52%
5 days
-11.56%
1 month
-22.62%
3 months
-36.27%
6 months
-65.05%
Year to date
-75.05%
1 year
-79.5%
5 years
-77.39%
10 years
-77.39%
 

About: BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.

Employees: 89

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 21.4%
Neutral 71.4%
Negative 7.1%
Neutral
Seeking Alpha
10 days ago
BioHarvest Sciences Inc. (BHST) Q3 2026 Earnings Call Transcript
BioHarvest Sciences Inc. (BHST) Q3 2026 Earnings Call Transcript
BioHarvest Sciences Inc. (BHST) Q3 2026 Earnings Call Transcript
Negative
Zacks Investment Research
10 days ago
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.14 per share a year ago.
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
Neutral
Newsfile Corp
10 days ago
BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update
Prioritizes cash preservation and controlled VINIA growth while concentrating CDMO resources on advanced programs with near-term manufacturing potential Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 12, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today reported financial results for the three and nine months ended September 30, 2026, and outlined its strategic priorities for 2027. The Company is aligning capital allocation, operating expenses and development resources with a narrower set of commercial objectives designed to preserve liquidity and advance its most promising Botanical Synthesis programs toward manufacturing.
BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update
Neutral
Newsfile Corp
24 days ago
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its third quarter 2026 financial results before the market opening on Thursday, November 12, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to discuss the results and provide an update on business operations.
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
Positive
Proactive Investors
1 month ago
BioHarvest takes second plant-cell asset to commercial readiness
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Tuesday that Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing, the second product from its Botanical Synthesis technology to reach that stage.  The company said Olive Cell has completed large-scale bioreactor scale-up, manufacturing readiness and a self-affirmed U.S. Generally Recognized as Safe (GRAS) process.
BioHarvest takes second plant-cell asset to commercial readiness
Neutral
Newsfile Corp
1 month ago
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization High-potency proprietary olive-derived Verbascoside composition demonstrates promising dose-dependent preclinical activity across liver steatosis and fibrosis models, with potential for development across multiple health and wellness categories Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ technology, today announced that its proprietary Olive Cell composition (Olive Cell) has reached commercial readiness and is now available for licensing and commercialization through the Company's CDMO business. This milestone marks the completion of BioHarvest's development pathway for Olive Cell - from plant-cell development and optimization through large-scale bioreactor scale-up, commercial manufacturing readiness and completion of the applicable self-affirmed U.S. Generally Recognized as Safe ("GRAS") process.
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Positive
Proactive Investors
1 month ago
BioHarvest says its platform can produce target sweetener in Tate & Lyle program
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday its Botanical Synthesis platform can produce the next-generation sweetener targeted in its joint development program with Tate & Lyle.  Tate & Lyle, a supplier of ingredient solutions for food and beverages, is looking to broaden its range of sweeteners as manufacturers seek ways to cut sugar and calories without losing taste and functionality, the companies said.
BioHarvest says its platform can produce target sweetener in Tate & Lyle program
Neutral
Newsfile Corp
1 month ago
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
Progress demonstrates that BioHarvest's Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solution Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme. The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution.
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
Positive
Proactive Investors
1 month ago
BioHarvest Sciences launches buyback of up to 5% of shares
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said Tuesday its board has authorized a share repurchase program covering up to 5% of its outstanding common shares.  The company, which develops and manufactures proprietary plant-based compositions for customers, partners and its own portfolio, will structure the program as a normal course issuer bid, in line with Canadian practice.
BioHarvest Sciences launches buyback of up to 5% of shares
Neutral
Newsfile Corp
1 month ago
BioHarvest Sciences Announces Share Repurchase Program
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in accordance with Canadian practices as a normal course issuer bid (the "NCIB"). The Company's Board of Directors believes that the market price of the Common Shares may not fully reflect the underlying value of the Company's business and future growth prospects.
BioHarvest Sciences Announces Share Repurchase Program
Price charts implemented using Lightweight Charts™